Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Klabunde

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Diabetes Technology & Therapeutics|June 23, 2016
Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes SimulatorRoberto Visentin, Clemens Giegerich, Robert Jäger, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 16, 2014
Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case studyMichela Riz, Morten Gram Pedersen, Gianna Maria Toffolo, et al.
Angewandte Chemie (International Ed. in English)|January 20, 2010
Drug design for G-protein-coupled receptors by a ligand-based NMR methodStefan Bartoschek, Thomas Klabunde, Elisabeth Defossa, et al.
Bioinformatics (Oxford, England)|December 3, 2015
IKAP: A heuristic framework for inference of kinase activities from Phosphoproteomics dataMarcel Mischnik, Francesca Sacco, Jürgen Cox, et al.
Protein Science : a Publication of the Protein Society|July 1, 2005
Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugsNikos G Oikonomakos, Magda N Kosmopoulou, Evangelia D Chrysina, et al.
Journal of Medicinal Chemistry|September 30, 2005
Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetesThomas Klabunde, K Ulrich Wendt, Dieter Kadereit, et al.
BMC Bioinformatics|November 19, 2025
Talk2Biomodels: AI agent-based open-source LLM initiative for kinetic biological modelsLilija Wehling, Gurdeep Singh, Ahmad Wisnu Mulyadi, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Diabetes Technology & Therapeutics|June 23, 2016
Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes SimulatorRoberto Visentin, Clemens Giegerich, Robert Jäger, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 16, 2014
Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case studyMichela Riz, Morten Gram Pedersen, Gianna Maria Toffolo, et al.
Angewandte Chemie (International Ed. in English)|January 20, 2010
Drug design for G-protein-coupled receptors by a ligand-based NMR methodStefan Bartoschek, Thomas Klabunde, Elisabeth Defossa, et al.
Bioinformatics (Oxford, England)|December 3, 2015
IKAP: A heuristic framework for inference of kinase activities from Phosphoproteomics dataMarcel Mischnik, Francesca Sacco, Jürgen Cox, et al.
Protein Science : a Publication of the Protein Society|July 1, 2005
Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugsNikos G Oikonomakos, Magda N Kosmopoulou, Evangelia D Chrysina, et al.
Journal of Medicinal Chemistry|September 30, 2005
Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetesThomas Klabunde, K Ulrich Wendt, Dieter Kadereit, et al.
BMC Bioinformatics|November 19, 2025
Talk2Biomodels: AI agent-based open-source LLM initiative for kinetic biological modelsLilija Wehling, Gurdeep Singh, Ahmad Wisnu Mulyadi, et al.
Pageof 3